Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00581919 · ClinicalTrials.gov registry record · Phase 2
Ph 2 Bortezomib, Dexamethasone, + Doxorubicin With ALCAR for Previously Treated Multiple Myeloma
A Phase 2 study, sponsored by University of Wisconsin, Madison.
- Completed
- Registry status
- Phase 2
- Development phase
- 32
- Enrollment target
NCT00581919 is a Phase 2 study that has completed, run by University of Wisconsin, Madison. The registered enrollment target is 32 participants.
The verdict
NCT00581919, a Phase 2 study, has completed, sponsored by University of Wisconsin, Madison.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 32 participants
- Enrollment target
Study Summary
Patients will receive Bortezomib, Dexamethasone, and Doxorubicin in 21 day cycles a total of 4 to 8 times (based on response to the treatment). Patients will also receive acetyl-L-carnitine (ALCAR) daily.
Interventions
- DRUG Bort, Dex, and Dox with ALCAR
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2004-02 |
| Est. Completion | 2013-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00581919
The ClinicalTrials.gov registry entry for NCT00581919 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Wisconsin, Madison, which has 1,039 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Bort, Dex, and Dox with ALCAR is the first listed.
NCT00581919 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00581919 about?
NCT00581919 is a clinical study titled "Ph 2 Bortezomib, Dexamethasone, + Doxorubicin With ALCAR for Previously Treated Multiple Myeloma". Patients will receive Bortezomib, Dexamethasone, and Doxorubicin in 21 day cycles a total of 4 to 8 times (based on response to the treatment). Patients will also receive acetyl-L-carnitine (ALCAR) daily.
What is the current status of trial NCT00581919?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2004-02. Estimated completion is 2013-07.
What interventions are being tested in trial NCT00581919?
The interventions under investigation include: Bort, Dex, and Dox with ALCAR (DRUG).
Who is sponsoring clinical trial NCT00581919?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.